United States Patent (19) 11 Patent Number: 6,069,254 Costanz0 Et Al

Total Page:16

File Type:pdf, Size:1020Kb

United States Patent (19) 11 Patent Number: 6,069,254 Costanz0 Et Al US006069254A United States Patent (19) 11 Patent Number: 6,069,254 Costanz0 et al. (45) Date of Patent: *May 30, 2000 54). CARBOXAMIDE DERIVATIVES OF 56) References Cited PPERDINE FOR THE TREATMENT OF THROMBOSIS DISORDERS U.S. PATENT DOCUMENTS 75 Inventors: Michael J. Costanzo, Ivyland; WilliamO O 5,639,765 6/1997 Ruminski ................................ 514/329 J. Hoekstra, Villanova; Bruce E. OTHER PUBLICATIONS Maryanoff, Forest Grove, all of Pa. Hoekstra et al., Bioorganic & Medicinal Chemistry Letters, 73 Assignee: Ortho Pharmaceutical Corp., Raritan, 6(20)pp. -2371-2376, Pergamon Press Oct. 20, 1996. N.J. Costa, B.R. et al., J. Med. Chem., 1994, 37(2), pp. 314-321, online Search results relied upon. * Notice: This patent issued on a continued pros ecution application filed under 37 CFR Primary Examiner Alan L. Rotman 1.53(d), and is subject to the twenty year Attorney, Agent, or Firm-Ralph R. Palo patent term provisions of 35 U.S.C. 154(a)(2). 57 ABSTRACT Carboxamide derivatives of pyrrolidine, piperidine, and 21 Appl. No.: 08/841,016 hexahydroazepine of formula (I): 22 Filed: Apr. 29, 1997 (I) Related U.S. Application Data 10 Rs 60 Provisional application No. 60/016,675, May 1, 1996. ( 51) Int. Cl." ...................... C07D 401/12; CO7D 401/14; N CO7D 403/14; A61K 31/445 X M-A 52 U.S. Cl. .......................... 546/189: 546/176; 546/187; 514/314; 514/316 are disclosed as useful in treating platelet-mediated throm 58 Field of Search ..................................... 546,193, 198, botic disorders. 546/208, 212, 187, 189, 176; 514/316, 318, 323,324, 314 2 Claims, No Drawings 6,069,254 1 2 CARBOXAMIDE DERVATIVES OF PIPERDINE FOR THE TREATMENT OF (I) THROMBOSIS DISORDERS R10 Rs This application claims benefit of Provisional Applica t tion number 60/016,675, filed May 1, 1996. N X BACKGROUND OF THE INVENTION M-A 1O Platelet aggregation constitutes the initial hemostatic wherein A, X, M, Rs, Rio, and n are as hereinafter defined. response to curtail bleeding induced by vascular injury. These platelet aggregation inhibitors are useful in treating However, pathological eXtension of this normal hemoStatic platelet-mediated thrombotic disorderS Such as arterial and proceSS can lead to thrombus formation. The final, common venous thrombosis, acute myocardial infarction, reocclusion pathway in platelet aggregation is the binding of fibrinogen 15 following thrombolytic therapy and angioplasty, to activated, exposed platelet glycoprotein IIb/IIIa (GPIb/ inflammation, unstable angina, and a variety of Vaso IIIa). Agents which interrupt binding of fibrinogen-to GPIb/ occlusive disorders. These compounds are also useful as IIIa, therefore, inhibit platelet aggregation. These agents are, antithrombotics used in conjunction with fibrinolytic therapy (e.g., t-PA or Streptokinase). Pharmaceutical com therefore, useful in treating platelet-mediated thrombotic positions containing Such compounds are also part of the disorderS Such as arterial and venous thrombosis, acute present invention. myocardial infarction, unstable angina, reocclusion follow ing thrombolytic therapy and angioplasty, inflammation, and DETAILED DESCRIPTION OF THE a variety of Vaso-occlusive disorders. The fibrinogen recep INVENTION tor (GPIb/IIIa) is activated by stimuli such as ADP, 25 More particularly, the present invention is directed to collagen, and thrombin exposing binding domains to two compounds of the following formula (I): different peptide regions of fibrinogen: C-chain Arg-Gly Asp (RGD) and Y-chain His-His-Leu-Gly-Gly-Ala-Lys-Gln (I) Ala-Gly-Asp-Val (HHLGGAKQAGDV, Y400-411). Since R10 R5 these peptide fragments themselves have been shown to inhibit fibrinogen binding to GPIIb/IIIa, a mimetic of these fragments would also serve as an antagonist. In fact, prior to tN this invention, potent RGD-based antagonists have been revealed which inhibit both fibrinogen binding to GPIb/IIIa 35 and platelet aggregation e.g., Ro-438857 (L. Alig, J. Med. Chem. 1992, 35, 4393) has an ICs of 0.094 uM against in wherein M is (CH), or piperidin-1-yl; Vitro thrombin-induced platelet aggregation. Some of these wherein A is Selected from any of piperidin-2-yl, agents have also shown in Vivo efficacy as antithrombotic piperidin-3-yl, pipe ridin-4-yl, pipe raZin-1-yl, agents and, in Some cases, have been used in conjunction 40 pyrrolidin-2-yl, pyrrolidin-3-yl, NHR, or with fibrinolytic therapy e.g., t-PA or Streptokinase, as well (J. A. Zablocki, Current Pharmaceutical Design 1995, 1, 533). As demonstrated by the results of the pharmacological Studies described hereinafter, the compounds of the present 45 N invention show the ability to block fibrinogen binding to isolated GPIb/IIIa (IC's 0.0002–1.39 uM), inhibit platelet aggregation in vitro in the presence of a variety of platelet wherein Ro is selected from any of H, alkyl, CH(NH), stimuli (0.019-65.0 uM vs. thrombin), and furthermore, CMe(NH) or acyl, preferably Ro is hydrogen; inhibit eX Vivo platelet aggregation in animal models. 50 wherein R is H or C(O)N(R')YZ Additionally, these agents exhibit efficacy in animal throm wherein R is selected from H or cycloalkyl; bosis models as their progenitors had shown ("Nipecotic wherein R is selected from any of H, alkyl or acyl. Acid Derivatives AS Antithrombotic Compounds,’ applica Preferably, R is hydrogen; tion Ser. No. 08/213,772, filed Mar. 16, 1994). The com 55 wherein Rs is H or C(O)NHQ(CHW),CORs; wherein Q pounds of the present invention show efficacy as antithrom is selected from CH, CH-aryl, CH-heteroaryl, botic agents by virtue of their ability to prevent platelet CH-substituted-heteroaryl or CH-alkyl; preferably Q is aggregation. Additionally, because the compounds of this CH, CH-substituted-heteroaryl or CH-heteroaryl; W is invention inhibit integrin-mediated cell-cell or cell-matrix selected from Hor N(R)T-R, preferably W is H when adhesion, they may also be useful against inflammation, 60 Q is CH, and N(R)-T-R, when Q is CH; wherein R bone resorption, tumor cell metastasis, etc. (D. Cox, Drug is Selected from any of H, alkyl or acyl, preferably R News&Perspectives 1995, 8, 197). is hydrogen, T is selected fron C(O), C(N-CN) or SO, preferably T is C(O) and R, is selected from any DISCLOSURE OF THE INVENTION of alkyl, aryl, aralkyl, alkoxy, or aminoalkyl, and Rs is 65 selected from H, alkyl or aralkyl; preferably Rs is H. The present invention is directed to compounds repre wherein m is the integer 1, 2, or 3. Preferably m is 1 or Sented by the following general formula (I): 2, 6,069,254 3 4 wherein X is selected from any of C(O), C(O)O, C(O)NH, n-hexyl, 2-hexyl and 2-methylpentyl. Alkoxy radicals are CH, or SO; oxygen ethers formed from the previously described Straight wherein n is the integer 1, 2, or 3; or branched chain alkyl groups. Cycloalkyl groups contain 5-8 ring carbons and preferably 6-7 carbons. wherein r is 0 or 1, The term “aryl”, “heteroaryl' or “substituted heteroaryl' wherein Y is selected from any of (CH), CH(R)(CH), as used herein alone or in combination with other terms (CH2)CH(R), (CH(COR")CH,), (CH2)CHOH or indicates aromatic or heteroaromatic groupS. Such as phenyl, piperidine-3-carboxylic acid; with the proviso that naphthyl, pyridyl, thienyl, furanyl, or quinolinyl wherein the when Y is (CH), and p is 2, X is other than C(O) or Substituent is an alkyl group. The term “aralkyl means an when X is C(O) then either R is other than H or R is alkyl group Substituted with an aryl group. other than H, and with the proviso that when Y is The term “acyl as used herein means an organic radical (CH(CO.R")CH.), X is other than C(O) or CH; having 2–6 carbon atoms derived from an organic acid by wherein p is 2 or 3; removal of the hydroxyl group. The compounds of the present invention may also be wherein q is 1, 2, or 3. Preferably, q is 1. present in the form of a pharmaceutically acceptable Salt. wherein R is alkyl, C-Cs alkenyl, C-Cs alkynyl, aryl, 15 The pharmaceutically acceptable Salt generally takes a form aralkyl or heteroaryl; in which the nitrogen on the 1-piperidine (pyrrolidine, wherein R" is H or alkyl or cycloalkyl. Preferably, R" is piperazine) Substituent is protonated with an inorganic or hydrogen. organic acid. Representative organic or inorganic acids wherein Z is COH, CO-alkyl, SOH, POH, or include hydrochloric, hydrobromic, hydriodic, perchloric, 5-tetrazole; provided that at least one of Rs and Rio is Sulfuric, nitric, phosphoric, acetic, propionic, glycolic, hydrogen; lactic, Succinic, maleic, fumaric, malic, tartaric, citric, or the enantiomer or the pharmaceutically acceptable Salt ben Zoic, man de lic, me thane Sulfonic, thereof. hydroxyethaneSulfonic, beneZeneSulfonic, oxalic, pamoic, Preferably, the group C(O)N(R')YZ is attached to the ring 2-naphthale n e Sulfonic, p - to lue n e Sulfonic, carbon of the central azacycle at the 3- or 4-position 25 cyclohexanesulfamic, Salicylic, Saccharinic or trifluoroace (4-position when larger than a five-membered ring), and tic. most preferably the 3-position. Particularly preferred compounds of the present invention AS used herein, unless otherwise noted alkyl and alkoxy include those compounds shown in Table 1, where “Subst” whether used alone or as part of a Substituent group, include indicates the position of attachment of the group C(O)N(R') Straight and branched chains having 1-8 carbons. For YCOH to the centralazacycle and where the letter “R” after example, alkyl radicals include methyl, ethyl, propyl, the numeral “3” indicates the absolute configuration (Cahn isopropyl, n-butyl, isobutyl, Sec-butyl, t-butyl, n-pentyl, Ingold-Prelog rules).
Recommended publications
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: wolfgang.froestl@acimmune.com GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • No Evidence of Altered in Vivobenzodiazepine Receptor Binding in Schizophrenia
    No Evidence of Altered In Vivo Benzodiazepine Receptor Binding in Schizophrenia Anissa Abi-Dargham, M.D., Marc Laruelle, M.D., John Krystal, M.D., Cyril D’Souza, M.D., Sami Zoghbi, Ph.D., Ronald M. Baldwin, Ph.D., John Seibyl, M.D., Osama Mawlawi, Ph.D., Gabriel de Erasquin, M.D., Ph.D., Dennis Charney, M.D., and Robert B. Innis, M.D., Ph.D. Deficits in gamma-amino-butyric acid (GABA) of this measurement was established in four healthy neurotransmitter systems have been implicated in the volunteers. No differences in regional BDZ VT were pathophysiology of schizophrenia for more than two observed between 16 male schizophrenic patients and 16 decades. Previous postmortem and in vivo studies of matched controls. No relationships were observed between benzodiazepine (BDZ) receptor density have reported BDZ VT and severity of psychotic symptoms in any of the alterations in several brain regions of schizophrenic regions examined. In conclusion, this study failed to patients. The goal of this study was to better characterize identify alterations of BDZ receptors density in possible alterations of the in vivo regional distribution schizophrenia. If this illness is associated with deficits in volume (VT) of BDZ receptors in schizophrenia, using the GABA transmission, these deficits do not substantially selective BDZ antagonist [123I]iomazenil and single photon involve BDZ receptor expression or regulation. emission computerized tomography (SPECT). Regional [Neuropsychopharmacology 20:650-661, 1999] BDZ VT was measured under sustained radiotracer © 1999 American College of Neuropsychopharmacology. equilibrium conditions. The reproducibility and reliability Published by Elsevier Science Inc. KEY WORDS: Schizophrenia; Benzodiazepine receptors; that disinhibition of dopamine function in schizophre- [123I]iomazenil; SPECT nia may stem from a deficit in inhibitory, GABA medi- ated systems (Roberts 1972; Stevens 1975; van Kammen Alterations of gamma-amino-butyric acid (GABA) sys- 1977).
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Alcohol and Violence: Neuropeptidergic Modulation of Monoamine Systems
    Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Addiction Reviews Alcohol and violence: neuropeptidergic modulation of monoamine systems Klaus A. Miczek,1,2 Joseph F. DeBold,2 Lara S. Hwa,2 Emily L. Newman,2 and Rosa M. M. de Almeida3 1Departments of Pharmacology, Psychiatry, and Neuroscience, Tufts University, Boston, Massachusetts. 2Department of Psychology, Tufts University, Medford, Massachusetts. 3Department of Psychology, LPNeC, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil Address for correspondence: Klaus A. Miczek, Department of Psychology, Tufts University, 530 Boston Ave (Bacon Hall), Medford, MA 02155. klaus.miczek@tufts.edu Neurobiological processes underlying the epidemiologically established link between alcohol and several types of social, aggressive, and violent behavior remain poorly understood. Acute low doses of alcohol, as well as withdrawal from long-term alcohol use, may lead to escalated aggressive behavior in a subset of individuals. An urgent task will be to disentangle the host of interacting genetic and environmental risk factors in individuals who are predisposed to engage in escalated aggressive behavior. The modulation of 5-hydroxytryptamine impulse flow by gamma- aminobutyric acid (GABA) and glutamate, acting via distinct ionotropic and metabotropic receptor subtypes in the dorsal raphe nucleus during alcohol consumption, is of critical significance in the suppression and escalation of aggressive behavior. In anticipation and reaction to aggressive behavior, neuropeptides such as corticotropin- releasing factor, neuropeptide Y, opioid peptides, and vasopressin interact with monoamines, GABA, and glutamate to attenuate and amplify aggressive behavior in alcohol-consuming individuals. These neuromodulators represent novel molecular targets for intervention that await clinical validation.
    [Show full text]
  • Tamás F. Freund
    BK-SFN-NEUROSCIENCE_V11-200147-Freund.indd 50 6/19/20 2:08 PM Tamás F. Freund BORN: Zirc, Hungary June 14, 1959 EDUCATION: Loránd Eötvös University, Budapest, Hungary, Biologist (1983) Semmelweis University, Budapest and Hungarian Academy of Sciences, PhD (1986) APPOINTMENTS: Postdoctoral Fellow, Anatomy, Semmelweis University–Hungarian Academy of Sciences (1986–1990) Visiting Research Fellow, MRC Unit, Pharmacology, Oxford University (1986–1988) Head of Department, Institute of Experimental Medicine, Hungarian Academy of Sciences (IEM-HAS), Budapest (1990–1994) Professor, IEM-HAS, Deputy Director (1994–2002) and Director (2002–present) Professor and Head of Department, Péter Pázmány Catholic University, Budapest (2000–present) HONORS AND AWARDS (SELECTED): Drs. C. and F. Demuth Swiss Medical Research Foundation Award, Switzerland (1991) KRIEG Cortical Kudos Cortical Explorer Award of the Cajal Club (1991, USA) KRIEG Cortical Kudos Cortical Discoverer Award and the Cajal Medal (1998, USA) Dargut and Milena Kemali Foundation Award, FENS Forum, Berlin (1998) Fellow, Hungarian Academy of Sciences (1998), Vice President (since 2014) Bolyai Prize (2000), Széchenyi Prize, (2005), Prima Primissima Award (2013, Hungary) Fellow, Academia Europaea (2000, London) and Academia Scientiarum et Artium Europaea (2001) Fellow, German Academy of Sciences Leopoldina (2001) President, Federation of European Neuroscience Societies (FENS, 2004–2006) The Brain Prize (2011, Grete Lundbeck Foundation, Denmark) Fellow, American Academy of Arts and Sciences (2014) Doctor Honoris Causa, University of Southern Finland (2015) Tamás Freund’s main achievements include the discovery of new molecular pathways in nerve cell communication, identity and principles of neuron connectivity fundamental to cortical circuitry, and the generation of network activity patterns underlying multiple stages of information processing and storage in the brain.
    [Show full text]
  • Diverse Small Molecules Prevent Macrophage Lysis During Pyroptosis Wendy P
    Loomis et al. Cell Death and Disease (2019) 10:326 https://doi.org/10.1038/s41419-019-1559-4 Cell Death & Disease ARTICLE Open Access Diverse small molecules prevent macrophage lysis during pyroptosis Wendy P. Loomis1, Andreas B. den Hartigh1,BradT.Cookson1,2 and Susan L. Fink 1 Abstract Pyroptosis is a programmed process of proinflammatory cell death mediated by caspase-1-related proteases that cleave the pore-forming protein, gasdermin D, causing cell lysis and release of inflammatory intracellular contents. The amino acid glycine prevents pyroptotic lysis via unknown mechanisms, without affecting caspase-1 activation or pore formation. Pyroptosis plays a critical role in diverse inflammatory diseases, including sepsis. Septic lethality is prevented by glycine treatment, suggesting that glycine-mediated cytoprotection may provide therapeutic benefit. In this study, we systematically examined a panel of small molecules, structurally related to glycine, for their ability to prevent pyroptotic lysis. We found a requirement for the carboxyl group, and limited tolerance for larger amino groups and substitution of the hydrogen R group. Glycine is an agonist for the neuronal glycine receptor, which acts as a ligand- gated chloride channel. The array of cytoprotective small molecules we identified resembles that of known glycine receptor modulators. However, using genetically deficient Glrb mutant macrophages, we found that the glycine receptor is not required for pyroptotic cytoprotection. Furthermore, protection against pyroptotic lysis is independent of extracellular chloride conductance, arguing against an effect mediated by ligand-gated chloride channels. Finally, we conducted a small-scale, hypothesis-driven small-molecule screen and identified unexpected ion channel modulators that prevent pyroptotic lysis with increased potency compared to glycine.
    [Show full text]
  • Supplementary Information
    Supplementary Information Supplementary Table S1. Classification of the GABA transporters. BGT1 GAT1 GAT2 GAT3 alternate Human hBGT1 hGAT1 hGAT2 hGAT3 Mouse mGAT2 mGAT1 mGAT4 mGAT3 Rat rGAT-A rGAT-B gene ID SLC6A12 SLC6A1 SLC6A13 SLC6A11 Accession number# BC019211 BC059080 AK149557 AK140423 Substrates GABA, Betaine GABA, GABA, GABA, Nipecotate β-Alanine β-Alanine Inhibitors NNC05-2090, Tiagabine, SNAP-5114 SNAP-5114, EF1502 SKF89976A, NNC05-2090 EF1502, NNC05-2090 #Accession number for cDNA used in the present study. Supplementary Table S2. IC50 (μM) of the GABA uptake inhibitors (substrates) in inhibiting [3H]GABA uptake by CHO cells stably expressing mouse GABA transporter subtypes. Cells in 48-well culture plate were incubated with 10 nM [3H]GABA for 10 min in the presence or absence of inhibitors. Uptake of [3H]GABA was determined in duplicate or triplicate from single experiment, and 3 IC50 was calculated using Prism5. Specific uptake of [ H]GABA by mGAT1, mGAT2, mGAT3 and mBGT1 in the absence of inhibitors was 8992.5, 2776.5, 2594.3 and 273.0 dpm/well, respectively. Inhibitors mGAT1 mGAT2 mGAT3 mBGT1 GABA 6.4 13 4.6 115 Nipecotic acid 9.7 113 86 7098 β-Alanine >300 25 18 >1000 Betaine >10000 >10000 >10000 693 Int. J. Mol. Sci. 2012, 13 2 Supplementary Figure S1. Inhibition of the GABA and serotonin transporters by antidepressants. Effects of amitryptiline (A), maprotilline (B), mianserine (C) and trimipramine (D) on uptake of [3H]GABA and [3H]5-HT was examined in the CHO cells stably expressing mouse GAT subtypes and rat SERT. Uptake assays were performed in 48-well plates for mGATs and 24-well plates for rSERT.
    [Show full text]
  • A Summary of Mechanistic Hypotheses of Gabapentin Pharmacology
    Epilepsy Research 29 (1998) 233–249 A summary of mechanistic hypotheses of gabapentin pharmacology Charles P. Taylor a,*, Nicolas S. Gee d, Ti-Zhi Su b, Jeffery D. Kocsis e, Devin F. Welty c, Jason P. Brown d, David J. Dooley a, Philip Boden d, Lakhbir Singh d a Department of Neuroscience Therapeutics, Parke–Da6is Pharmaceutical Research, Di6ision of Warner–Lambert Co., Ann Arbor, MI 48105, USA b Department of Molecular Biology, Parke–Da6is Pharmaceutical Research, Di6ision of Warner–Lambert Co., Ann Arbor, MI 48105, USA c Department of Pharmacokinetics and Drug Metabolism, Parke–Da6is Pharmaceutical Research, Di6ision of Warner–Lambert Co., Ann Arbor, MI 48105, USA d Parke–Da6is Neuroscience Research Centre, Cambridge Uni6ersity For6ie Site, Robinson Way, Cambridge, CB22QB, UK e Neuroscience and Regeneration Research Center A127A, Veterans Affairs Medical Center, Building 34, Room 123, 950 Campbell A6e., West Ha6en, CT 06516, USA Received 28 July 1997; received in revised form 1 October 1997; accepted 8 October 1997 Abstract Although the cellular mechanisms of pharmacological actions of gabapentin (Neurontin®) remain incompletely described, several hypotheses have been proposed. It is possible that different mechanisms account for anticonvulsant, antinociceptive, anxiolytic and neuroprotective activity in animal models. Gabapentin is an amino acid, with a mechanism that differs from those of other anticonvulsant drugs such as phenytoin, carbamazepine or valproate. Radiotracer studies with [14C]gabapentin suggest that gabapentin is rapidly accessible to brain cell cytosol. Several hypotheses of cellular mechanisms have been proposed to explain the pharmacology of gabapentin: 1. Gabapentin crosses several membrane barriers in the body via a specific amino acid transporter (system L) and competes with leucine, isoleucine, valine and phenylalanine for transport.
    [Show full text]
  • The Concise Guide to Pharmacology 2019/20: Transporters
    University of Dundee The Concise Guide to Pharmacology 2019/20 CGTP Collaborators; Alexander, Stephen P. H.; Kelly, Eamonn; Mathie, Alistair; Peters, John A.; Veale, Emma L. Published in: British Journal of Pharmacology DOI: 10.1111/bph.14753 Publication date: 2019 Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): CGTP Collaborators, Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., ... Davies, J. A. (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176 (S1), S397- S493. https://doi.org/10.1111/bph.14753 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Dec. 2019 S.P.H. Alexander et al. The Concise
    [Show full text]
  • Product Information Sheet
    GABAERGIC LIGAND-SET™ Product Number L7884 Storage Temperature -20°C Product Description trafficking protein, as no binding site for GABA or any The GABAergic LIGAND-SET™ is a set of 40 small modulators have been detected on GBR2. It is organic ligands that modulate GABA receptors. These possible that the two function together to amplify ligands are arrayed in a standard 96-well plate format; , GABAegic signaling. each well has a capacity of 1 ml. GABAC receptors were first proposed in 1986 to This set can be used for screening new drug targets, for describe a bicuculline- and baclofen-insensitive [3H]- guiding secondary screens of larger, more diverse GABA binding site on cerebellar membranes. They libraries and for standardizing and validating new have subsequently been shown to be ligand-gated screening assays. chloride channels. These receptors are highly sensitive to GABA, but are not blocked by traditional GABAA There are three classes of g-aminobutyric acid (GABA) receptor antagonists. Furthermore, they are not receptors, GABAA, GABAB and GABAC. GABAA and modulated by GABAA receptor modulators. Finally, GABAC are ligand gated ion channels, while GABAB is GABAC receptors are insensitive to baclofen, a highly a G protein-coupled receptor. There are two isoforms selective GABAB receptor agonist, and to phaclofen and of GABAB receptors: GBR1a and GBR1b (molecular saclofen, two GABAB receptor antagonists. Most of the weight of 130 kDa and 92 kDa, respectively). knowledge of GABAC receptors comes from studies of the visual system, however evidence does exist that GABAA receptor activation induces a cascade of events they are present in other brain regions.
    [Show full text]
  • Y-Aminobutyric Acid Uptake by a Bacterial System With
    Proc. Nati. Acad. Sci. USA Vol. 86, pp. 7378-7381, October 1989 Biochemistry y-Aminobutyric acid uptake by a bacterial system with neurotransmitter binding characteristics (muscimol/type A y-aminobutyric acid receptor/Pseudomonas fluorescens) GEORGE D. GUTHRIE* AND CATHERINE S. NICHOLSON-GUTHRIEt *Department of Biochemistry, tSchool of Medicine, Indiana University, 700 Drexel Drive, Evansville, IN 47712 Communicated by Robert L. Sinsheimer, July 3, 1989 (received for review February 13, 1989) ABSTRACT y-Aminobutyric acid (GABA), an amino soak as judged by their stable OD and retention of motility. acid, has been found in every class of living organisms. In Ten milliliters of cells was centrifuged at 1200 X g for about higher organisms, GABA is a neurotransmitter and binds with 3 sec to remove debris; 5 ml of cell suspension was removed, high affinity and specificity to GABA receptors on neurons in centrifuged (3000 x g, 10 min), washed twice with Tris citrate a sodium-independent reaction that is saturable. The role of buffer, resuspended to an OD of 0.15, and resoaked for 1 hr. GABA in organisms lacking nervous tissue is not known. This GABA Assay. Preliminary chase experiments with unla- report describes, in a strain of Pseudomonas fluorescens, a beled GABA showed that the radioactivity remained bound GABA uptake system with binding characteristics like those of after a chase. Hence, direct measurement of GABA binding the GABA (type A) brain receptor. The binding was saturable to determine a dissociation constant (Kd) was not possible. and specific for GABA, was sodium-independent, was of high Consequently, the GABA assay was designed to measure the affinity (Km = 65 nM), and was inhibited competitively by Michaelis constant (Kin) from which characteristics of the muscimol, a potent GABA analogue.
    [Show full text]